Synthetic conjugated estrogens, B tablets contain a blend of ten synthetic estrogenic substances. The estrogenic substances are: sodium estrone sulfate, sodium equilin sulfate, sodium 17?-dihydroequilin sulfate, sodium 17?-estradiol sulfate, sodium 17? dihydroequilin sulfate, sodium 17?-dihydroequilenin sulfate, sodium 17?-dihydroequilenin sulfate, sodium equilenin sulfate, sodium 17?-estradiol sulfate, and sodium ?8,9-dehydroestrone sulfate. This blend of ten estrogen derivatives are plant-derived forms of endogenous estrogens and contain many of the same compounds as the Conjugated Equine Estrogens (CEEs), although they are not considered to be equivalent. Available as the product Cenestin (FDA), this combination of plant-derived estrogenic compounds is indicated for the treatment of moderate to severe vasomotor symptoms, vulvovaginal atrophy, vaginal dryness, and paint with intercourse associated with menopause.
All estrogen products mimic the effects of endogenous estrogens in the body which are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estrogens act by binding to estrogen receptors on a wide variety of tissues in the body and modulating the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH) through a negative feedback mechanism. Prior to menopause, the primary source of estrogen is the ovarian follicle, which secretes 70-500 micrograms of estradiol daily, depending on the phase of the menstrual cycle. However, once a woman stops ovulating there is a sharp decline in the production of progesterone and estradiol by the ovaries and a consequent fluctuation in LH and FSH due to a lack of feedback control. This shift in hormone production is largely responsible for many of the symptoms experienced during and after menopause and includes hot flashes and other vasomotor symptoms, painful intercourse, vaginal dryness, and vulvovaginal atrophy. These symptoms are able to be reduced by replacing many of the hormones lost during and following menopause with synthetic or naturally occurring forms, in a therapy known as Hormone Replacement Therapy (HRT).
Pharmacologic estrogen products are available in a variety of formats. Although many of them contain several compounds in common (such as the estrogen derivatives sodium estrone sulfate and sodium equilin sulfate), they vary by their original source (such as horse-, human-, or plant-derived), and the remaining mixture of estrogenic derivatives. Conjugated Equine Estrogens (CEEs) are derived from the urine of pregnant mares and contain a blend of at least 10 estrogen derivatives. Marketed under the brand name Premarin, CEEs are the most frequently used form of conjugated estrogens. There is currently no generic form of CEEs available as a detailed analytical characterization of the active ingredients or of their estrogenic activity is not available at this time. Conjugated estrogens are also available in a plant-derived synthetic form that replicates the naturally occurring, horse-derived forms. Available as either "Synthetic Conjugated Estrogens, A" containing 9 estrogen derivatives (available as Cenestin) or as "Synthetic Conjugated Estrogens, B" containing 10 estrogen derivatives (available as Enjuvia), these products are isolated as precursors from yam or soy plants and then chemically modified to mimic the products available in their naturally occurring form.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Prasterone | The risk or severity of adverse effects can be increased when Prasterone is combined with Synthetic Conjugated Estrogens, B. |
| Exemestane | The therapeutic efficacy of Exemestane can be decreased when used in combination with Synthetic Conjugated Estrogens, B. |
| Hyaluronidase (ovine) | The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Synthetic Conjugated Estrogens, B. |
| Hyaluronidase (human recombinant) | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Synthetic Conjugated Estrogens, B. |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Synthetic Conjugated Estrogens, B. |
| Lenalidomide | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Lenalidomide. |
| Ospemifene | The risk or severity of adverse effects can be increased when Synthetic Conjugated Estrogens, B is combined with Ospemifene. |
| Ropinirole | Synthetic Conjugated Estrogens, B may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy. |
| Thalidomide | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Thalidomide. |
| Cetuximab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Cetuximab. |
| Human immunoglobulin G | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Human immunoglobulin G. |
| Omalizumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Omalizumab. |
| Gemtuzumab ozogamicin | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Indium In-111 satumomab pendetide | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Trastuzumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Trastuzumab. |
| Rituximab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Rituximab. |
| Basiliximab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Basiliximab. |
| Muromonab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Muromonab. |
| Digoxin Immune Fab (Ovine) | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Ibritumomab tiuxetan | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Alemtuzumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Alemtuzumab. |
| Capromab pendetide | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Capromab pendetide. |
| Efalizumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Efalizumab. |
| Antithymocyte immunoglobulin (rabbit) | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit). |
| Natalizumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Natalizumab. |
| Palivizumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Palivizumab. |
| Daclizumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Daclizumab. |
| Bevacizumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Bevacizumab. |
| Technetium Tc-99m arcitumomab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Eculizumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Eculizumab. |
| Panitumumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Panitumumab. |
| Ranibizumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Ranibizumab. |
| Galiximab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Galiximab. |
| Pexelizumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Pexelizumab. |
| Epratuzumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Epratuzumab. |
| Bectumomab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Bectumomab. |
| Oregovomab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Oregovomab. |
| IGN311 | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of IGN311. |
| Adecatumumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Adecatumumab. |
| Labetuzumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Labetuzumab. |
| Matuzumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Matuzumab. |
| Fontolizumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Fontolizumab. |
| Bavituximab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Bavituximab. |
| CR002 | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of CR002. |
| Rozrolimupab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Rozrolimupab. |
| Girentuximab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Girentuximab. |
| Obiltoxaximab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Obiltoxaximab. |
| XTL-001 | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of XTL-001. |
| NAV 1800 | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of NAV 1800. |
| Briakinumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Briakinumab. |
| Otelixizumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Otelixizumab. |
| AMG 108 | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of AMG 108. |
| Iratumumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Iratumumab. |
| Enokizumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Enokizumab. |
| Ramucirumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Ramucirumab. |
| Farletuzumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Farletuzumab. |
| Veltuzumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Veltuzumab. |
| Ustekinumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Ustekinumab. |
| PRO-542 | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of PRO-542. |
| TNX-901 | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of TNX-901. |
| Inotuzumab ozogamicin | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| RI 624 | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of RI 624. |
| Stamulumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of MYO-029. |
| CT-011 | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of CT-011. |
| Leronlimab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Leronlimab. |
| Glembatumumab vedotin | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Glembatumumab vedotin. |
| Olaratumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Olaratumab. |
| IPH 2101 | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of IPH 2101. |
| TB-402 | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of TB-402. |
| Caplacizumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Caplacizumab. |
| IMC-1C11 | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of IMC-1C11. |
| Eldelumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Eldelumab. |
| Lumiliximab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Lumiliximab. |
| Nimotuzumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Nimotuzumab. |
| Clenoliximab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Clenoliximab. |
| BIIB015 | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of BIIB015. |
| Sonepcizumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Sonepcizumab. |
| Motavizumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Motavizumab. |
| Elotuzumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Elotuzumab. |
| Carotuximab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Carotuximab. |
| XmAb 2513 | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of XmAb 2513. |
| Lucatumumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Lucatumumab. |
| Pertuzumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Pertuzumab. |
| Siplizumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Siplizumab. |
| Apolizumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Apolizumab. |
| Sibrotuzumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Sibrotuzumab. |
| Bivatuzumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Bivatuzumab. |
| Lerdelimumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Lerdelimumab. |
| Lexatumumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Lexatumumab. |
| Reslizumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Reslizumab. |
| Teplizumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Teplizumab. |
| Catumaxomab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Catumaxomab. |
| Mepolizumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Mepolizumab. |
| Denosumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Denosumab. |
| Volociximab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Volociximab. |
| Ofatumumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Ofatumumab. |
| Belimumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Belimumab. |
| Raxibacumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Raxibacumab. |
| Obinutuzumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Obinutuzumab. |
| Vedolizumab | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Vedolizumab. |